SPY304.32+1.35 0.45%
DIA254.29-0.06 -0.02%
IXIC9,489.87+120.88 1.29%

Wedbush Upgrades Arbutus Biopharma to Outperform, Raises Price Target of $4

Wedbush analyst Robert Driscoll upgrades Arbutus Biopharma (NASDAQ:ABUS) from Neutral to Outperform and raises the price target from $2 to $4.

Benzinga · 05/19/2020 12:26

Wedbush analyst Robert Driscoll upgrades Arbutus Biopharma (NASDAQ:ABUS) from Neutral to Outperform and raises the price target from $2 to $4.